The CB1 antagonist Rimonabant (Acomplia, Sanofi-Aventis) was initially developed for the treatment of obesity, and its effect was better than expected [9–11]. This evidence concerns the gene CNR1 and obesity due to melanocortin 4 receptor deficiency.